David Westenberg

Davis declined to give Shield volumes and reframed toward Haystack clinical evidence and assay performance.

Jim described future physical: wearable data + labs done before doctor visit, fed into AI engine producing reports for both patient and physician. Cited March Nature article from Google Health/Fitbit/Quest study on biomarker-biometric linkage. Expects increasing trend of consumers testing biomarkers longitudinally.

Jim said Quest is working on home collection beyond fingerpricks. Self-collect for STDs and HPV currently requires PSC visit but future plans for home use.

Sam confirmed payer mix shift driven by LifeLabs revenue addition. Jim said wage inflation steady at 3-4%, attrition in mid-teens approaching pre-pandemic levels.

Jim detailed benefits: improved data analytics for pharma/CRO clients, faster employee database searches, AI-based chat for physicians and patients, and test menu navigation via GenAI.

Jim detailed 6% acquisition contribution in 2025, with over two-thirds from LifeLabs. Sam clarified LifeLabs integration is lighter (standalone entity), and tuck-in M&A capital allocated for 2025.

Wetteny declined to split the deterioration precisely but said both macro and competitive factors are meaningfully impactful and converge; cited category visits down and Cytopoint as largely macro.

Wetteny confirmed no significant shift in pricing approach. Product-by-product, market-by-market value-based pricing remains consistent. Leveraging broad portfolio to drive volumes with customers where legally allowed. Pipeline innovation provides additional leverage.

Kristin highlighted 3 differentiated offerings: Apoquel (10+ years safety data), Apoquel Chew (convenient, no food required), and Cytopoint (long-acting injectable). Long-acting Cytopoint approval expected in 12-36 months. Wetteny added $20M undertreated dogs are already medicalized.

Kristin confirmed no pipeline delays at FDA or USDA despite workforce cuts, and described active engagement with administration to shape regulatory environment.

Kristin cited 40% retail growth and 21% US share from alternative channels. Wetteny added economics are neutral to positive and company is well positioned across all channels.

Jacob highlighted deeper academic core-lab relationships, Dr. Eric Green's hire, and Illumina's tradition of delivering output above spec as a customer benefit.

Jacob said most clinical customers expand assays rather than just cut cost when moving to X; Ankur reiterated the transition is lumpy, not linear.

Jacob framed mid-throughput weakness as macro-driven with some competition; Ankur confirmed performance obligations up double digits year-over-year.

Jacob described DRAGEN on GPU and foundational-model enablement as a network-effect driver beyond genomics.

Adam gave a balanced answer, framing self-collection as complementary to phlebotomy rather than a replacement, with different economics on each path.

Adam confirmed continued investment in OnDemand and consumer advertising. Decided not to compete in some consumer segments where pricing floor is uncertain. Prioritizing specialty areas with strong reimbursement, higher margins, and medical unmet need over volume-driven consumer plays.

Adam confirmed 3-4x growth rate in specialty areas has been consistent (not accelerating). Oncology strategy broken into three pillars: screening (follower), therapy selection (leader), MRD monitoring (aspiring leader). Scale and breadth as competitive advantages.

Adam addressed accretion coming from cost takeout and best-of-best asset selection on MRD. Did not directly address IP disputes or reimbursement timelines.

Jay explained international markets are earlier in diagnostics adoption with blood work at ~1/3 US levels. Andrew confirmed no meaningful tariff pull-forward in order patterns due to paper-run revenue model.

Jay noted 360 remains the majority placement vehicle. EVI was double-digit globally with strong competitive and greenfield catalyst quality across US and international.

Jay confirmed some cat mix shift and highlighted IDXX's SDMA and fecal antigen products as well-positioned for cat care. Pet population flat YoY at ~3% CAGR vs 2019.

Eric argued AI reimbursement must eventually come and Tempus is well positioned when it does.

Jim explained Genomics follows lab seasonality while Data is back-half weighted to pharma budgets.